EX-99.2 3 a2022q3exhibit992.htm EX-99.2 Document

Exhibit 99.2


Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
THIRD QUARTER
Percent Change
20222021TotalOperationsCurrency
Sales to customers by
geographic area
U.S.$12,453  11,963  4.1 % 4.1 — 
Europe 5,524  5,587 (1.1) 14.5  (15.6)
Western Hemisphere excluding U.S. 1,562  1,500  4.1 9.1  (5.0)
Asia-Pacific, Africa 4,252  4,288  (0.9) 10.5  (11.4)
International 11,338  11,375  (0.3) 12.3  (12.6)
      
Worldwide$23,791  23,338  1.9 % 8.1  (6.2)
        
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.





Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
NINE MONTHS
Percent Change
20222021TotalOperationsCurrency
Sales to customers by
geographic area
U.S.$36,064  34,993 3.1 %3.1 — 
Europe 17,633  16,669  5.8  18.2  (12.4)
Western Hemisphere excluding U.S. 4,580  4,291  6.7  9.6  (2.9)
Asia-Pacific, Africa 12,960  13,018  (0.4) 7.2  (7.6)
International 35,173  33,978  3.5  12.9  (9.4)
      
Worldwide$71,237  68,971  3.3 % 7.9  (4.6)
        
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.



Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
THIRD QUARTER
 Percent Change
20222021TotalOperationsCurrency
Sales to customers by
segment of business
Consumer Health (1)
    U.S.$1,659 1,625 2.1 %2.1 — 
    International2,136 2,187 (2.3)6.7 (9.0)
3,795    3,812 (0.4)4.7 (5.1)
Pharmaceutical (1)
    U.S.7,438 7,221 3.0 3.0— 
    International5,776 5,661 2.0 16.7(14.7)
13,214    12,882 2.6 9.0(6.4)
Pharmaceutical excluding COVID-19 Vaccine (1,3)
     U.S.7,438 6,951 7.0 7.0— 
     International5,287 5,429 (2.6)11.3(13.9)
12,725 12,380 2.8 8.9(6.1)
MedTech (2)
    U.S.3,356    3,117 7.7 7.7 — 
    International3,426 3,527 (2.9)8.5 (11.4)
 6,782    6,644 2.1 8.1 (6.0)
U.S.12,453 11,963 4.1 4.1 — 
International11,338 11,375 (0.3)12.3 (12.6)
Worldwide23,791 23,338 1.9 8.1 (6.2)
   
U.S.12,453 11,693 6.5 6.5 — 
International10,849 11,143 (2.6)9.5 (12.1)
Worldwide excluding COVID-19 Vaccine (3)
$23,302 22,836 2.0 %8.0 (6.0)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1) Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes.
(2) Previously referred to as Medical Devices.
(3) Refer to supplemental sales reconciliation schedule




Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
NINE MONTHS
 Percent Change
20222021TotalOperationsCurrency
Sales to customers by
segment of business
Consumer Health (1)
    U.S.$4,903 4,987 (1.7)%(1.7)— 
    International6,283 6,320 (0.6)6.0 (6.6)
11,186    11,307 (1.1)2.6 (3.7)
Pharmaceutical (1)
    U.S.21,229 20,536 3.4 3.4— 
    International18,171 16,927 7.3 18.5(11.2)
39,400    37,463 5.2 10.2(5.0)
Pharmaceutical excluding COVID-19 Vaccine (1,3)
     U.S.21,109 20,115 4.9 4.9— 
     International16,801 16,582 1.3 11.7(10.4)
37,910 36,697 3.3 8.0(4.7)
MedTech (2)
    U.S.9,932    9,470 4.9 4.9 — 
    International10,719 10,731 (0.1)8.2 (8.3)
 20,651    20,201 2.2 6.6 (4.4)
U.S.36,064 34,993 3.1 3.1 — 
International35,173 33,978 3.5 12.9 (9.4)
Worldwide71,237 68,971 3.3 7.9 (4.6)
   
U.S.35,944 34,572 4.0 4.0 — 
International33,803 33,633 0.5 9.5 (9.0)
Worldwide excluding COVID-19 Vaccine (3)
$69,747 68,205 2.3 %6.7 (4.4)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1) Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes.
(2) Previously referred to as Medical Devices.
(3) Refer to supplemental sales reconciliation schedule


Johnson & Johnson and Subsidiaries 
Condensed Consolidated Statement of Earnings  
(Unaudited; in Millions Except Per Share Figures)
THIRD QUARTER
20222021Percent
PercentPercentIncrease
Amountto SalesAmountto Sales(Decrease)
Sales to customers$23,791 100.0$23,338 100.01.9 
Cost of products sold7,807 32.87,250 31.17.7 
Gross Profit15,984 67.216,088 68.9(0.6)
Selling, marketing and administrative expenses6,089 25.66,000 25.71.5 
Research and development expense3,597 15.13,422 14.75.1 
In-process research and development— — 900 3.9  
Interest (income) expense, net(99)(0.4)7 0.0 
Other (income) expense, net493 2.1 1,850 7.9  
Restructuring82 0.360 0.2 
Earnings before provision for taxes on income5,822 24.53,849 16.551.3 
Provision for taxes on income1,364 5.8182 0.8 649.5 
Net earnings$4,458 18.7$3,667 15.721.6 
Net earnings per share (Diluted)$1.68 $1.37 22.6 
Average shares outstanding (Diluted)2,661.3 2,674.9 
Effective tax rate23.4 %4.7 %
Adjusted earnings before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income$8,073 33.9$8,058 34.50.2 
Net earnings$6,779 28.5$6,968 29.9(2.7)
Net earnings per share (Diluted)$2.55 $2.60 (1.9)
Effective tax rate16.0 %13.5 %
(1) See Reconciliation of Non-GAAP Financial Measures.
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.



Johnson & Johnson and Subsidiaries 
Condensed Consolidated Statement of Earnings  
(Unaudited; in Millions Except Per Share Figures)
NINE MONTHS
20222021Percent
PercentPercentIncrease
Amountto SalesAmountto Sales(Decrease)
Sales to customers$71,237 100.0$68,971 100.03.3 
Cost of products sold23,324 32.721,900 31.86.5 
Gross Profit47,913 67.347,071 68.21.8 
Selling, marketing and administrative expenses18,253 25.717,505 25.44.3 
Research and development expense10,762 15.19,994 14.57.7 
In-process research and development6100.9900 1.3  
Interest (income) expense, net(137)(0.2)83 0.1 
Other (income) expense, net664 0.9 480 0.7  
Restructuring237 0.3169 0.2 
Earnings before provision for taxes on income17,524 24.617,940 26.0(2.3)
Provision for taxes on income3,103 4.41,798 2.6 72.6 
Net earnings$14,421 20.2$16,142 23.4(10.7)
Net earnings per share (Diluted)$5.41 $6.04 (10.4)
Average shares outstanding (Diluted)2,667.5 2,674.6 
Effective tax rate17.7 %10.0 %
Adjusted earnings before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income$24,462 34.3$24,125 35.01.4 
Net earnings$20,820 29.2$20,517 29.71.5 
Net earnings per share (Diluted)$7.81 $7.67 1.8 
Effective tax rate14.9 %15.0 %
(1) See Reconciliation of Non-GAAP Financial Measures.
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.


Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Third Quarter
(Dollars in Millions Except Per Share Data)20222021
Net Earnings, after tax- as reported$4,458$3,667
Pre-tax Adjustments
Intangible Asset Amortization expense1,041 1,159
Litigation related219 2,077
IPR&D -  900
Restructuring related123 121
Acquisition, integration and divestiture related - 20
(Gains)/losses on securities 164 (127)
Medical Device Regulation 1
78  59
COVID-19 Vaccine related costs 2
377 -
Consumer Health separation costs249  -
Other -  -
Tax Adjustments
Tax impact on special item adjustments 3
(379)(849)
Consumer Health separation tax related costs361  -
Tax legislation and other tax related88  (59)
Adjusted Net Earnings, after tax$6,779 $6,968 
Average shares outstanding (Diluted)2,661.3 2,674.9 
Adjusted net earnings per share (Diluted)$2.55 $2.60 
Operational adjusted net earnings per share (Diluted)$2.75 
Notes:
1
European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance which is expected to be completed during 2024.
2
COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's modification of its COVID-19 vaccine research program and manufacturing capacity to levels that meet all customer contractual requirements.
3
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.




Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Nine Months Ended
(Dollars in Millions Except Per Share Data)20222021
Net Earnings, after tax- as reported$14,421$16,142
Pre-tax Adjustments
Intangible Asset Amortization expense3,244 3,576
Litigation related604 2,054
IPR&D 610  900
Restructuring related323 333
Acquisition, integration and divestiture related 1
 - (504)
(Gains)/losses on securities 684 (335)
Medical Device Regulation 2
208  161
COVID-19 Vaccine related costs 3
653  -
Consumer Health separation costs619 -
Other(7) -
Tax Adjustments
Tax impact on special item adjustments 4
(1,085)(1,097)
Consumer Health separation tax related costs459  -
Tax legislation and other tax related87  (713)
Adjusted Net Earnings, after tax$20,820$20,517
Average shares outstanding (Diluted)2,667.5 2,674.6 
Adjusted net earnings per share (Diluted)$7.81 $7.67 
Operational adjusted net earnings per share (Diluted)$8.25  
Notes:
1
Acquisition, integration and divestiture related for the nine months of 2021 primarily includes the gain on the divestiture of two Pharmaceutical brands outside of the U.S.
2
European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance which is expected to be completed during 2024.
3
COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's modification of its COVID-19 vaccine research program and manufacturing capacity to levels that meet all customer contractual requirements.
4
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.


Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Adjusted Operational Sales Growth (A)
 THIRD QUARTER 2022 ACTUAL vs. 2021 ACTUAL
 Segments
Consumer Health Pharmaceutical  MedTech  Total
 WW As Reported (0.4)%2.6 %2.1 %1.9 %
 U.S. 2.1 %3.0 %7.7 %4.1 %
 International (2.3)%2.0 %(2.9)%(0.3)%
 WW Currency (5.1)(6.4)(6.0)(6.2)
 U.S. ————
 International (9.0)(14.7)(11.4)(12.6)
 WW Operational 4.7 %9.0 %8.1 %8.1 %
 U.S. 2.1 %3.0 %7.7 %4.1 %
 International 6.7 %16.7 %8.5 %12.3 %
All Other Acquisitions and Divestitures0.10.20.00.1
 U.S. 0.20.2(0.2)0.1
 International 0.00.10.20.1
WW Adjusted Operational4.8 %9.2 %8.1 %8.2 %
 U.S. 2.3 %3.2 %7.5 %4.2 %
 International 6.7 %16.8 %8.7 %12.4 %
Note: Percentages are based on actual, non-rounded figures and may not sum
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Adjusted Operational Sales Growth (A)
NINE MONTHS 2022 ACTUAL vs. 2021 ACTUAL
 Segments
Consumer Health Pharmaceutical MedTech Total
 WW As Reported (1.1)%5.2 %2.2 %3.3 %
 U.S. (1.7)%3.4 %4.9 %3.1 %
 International (0.6)%7.3 %(0.1)%3.5 %
 WW Currency (3.7)(5.0)(4.4)(4.6)
 U.S. ————
 International (6.6)(11.2)(8.3)(9.4)
 WW Operational 2.6 %10.2 %6.6 %7.9 %
 U.S. (1.7)%3.4 %4.9 %3.1 %
 International 6.0 %18.5 %8.2 %12.9 %
All Other Acquisitions and Divestitures0.50.10.10.2
 U.S. 0.20.1(0.2)0.1
 International 0.70.10.20.2
WW Adjusted Operational3.1 %10.3 %6.7 %8.1 %
 U.S. (1.5)%3.5 %4.7 %3.2 %
 International 6.7 %18.6 %8.4 %13.1 %
Note: Percentages are based on actual, non-rounded figures and may not sum
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.



Johnson & Johnson
Segment Sales
(Dollars in Millions)
THIRD QUARTER
% Change
20222021Reported
Operational (1)
Currency
CONSUMER HEALTH SEGMENT (2) (3)
OTC
US$6956861.4 %1.4 %— %
Intl8257983.4 12.2 (8.8)
WW1,5191,4842.5 7.2 (4.7)
SKIN HEALTH / BEAUTY
US5915693.7 3.7 — 
Intl535555(3.6)6.2 (9.8)
WW1,126 1,1240.1 5.0 (4.9)
ORAL CARE
US1581505.2 5.2 — 
Intl217248(12.4)(4.3)(8.1)
WW375 398 (5.8)(0.7)(5.1)
BABY CARE
US9195(4.0)(4.0)— 
Intl283296(4.5)3.4 (7.9)
WW375 391 (4.3)1.6 (5.9)
WOMEN'S HEALTH
US23(22.0)(22.0)— 
Intl222229(2.7)8.4 (11.1)
WW225232(3.0)7.9 (10.9)
WOUND CARE / OTHER
US122122(0.2)(0.2)— 
Intl5361(11.4)(7.1)(4.3)
WW176182(3.9)(2.5)(1.4)
TOTAL CONSUMER HEALTH
US1,659 1,625 2.1 2.1 — 
Intl2,136 2,187 (2.3)6.7 (9.0)
WW$3,795 3,812 (0.4)%4.7 %(5.1)%
See footnotes at end of schedule





Johnson & Johnson
Segment Sales
(Dollars in Millions)
THIRD QUARTER
% Change
20222021Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3)
IMMUNOLOGY
US$2,8762,7713.8 %3.8 %— %
Intl1,4111,480(4.7)8.9 (13.6)
WW4,2874,2500.9 5.6 (4.7)
     REMICADE
     US350480(27.0)(27.0)— 
     US Exports (4)
3947(16.9)(16.9)— 
     Intl169234(27.8)(22.8)(5.0)
     WW558761(26.6)(25.1)(1.5)
     SIMPONI / SIMPONI ARIA
     US2982950.9 0.9 — 
     Intl248276(10.4)3.0 (13.4)
     WW545571(4.6)1.9 (6.5)
     STELARA
     US1,6551,5695.5 5.5 — 
     Intl794809(1.9)12.9 (14.8)
     WW2,4492,3783.0 8.0 (5.0)
     TREMFYA
     US530 376 40.7 40.7 — 
     Intl200 161 24.6 44.5 (19.9)
     WW729 537 35.9 41.9 (6.0)
     OTHER IMMUNOLOGY
     US5 3 **— 
     Intl0 0 **  *
     WW5 3 **  *
INFECTIOUS DISEASES
US390679(42.7)(42.7)— 
Intl90569829.749.1(19.4)
WW1,2951,378(6.0)3.8(9.8)
     COVID-19 VACCINE
     US0270**— 
     Intl489233**  *
     WW489502(2.7)13.1(15.8)
     EDURANT / rilpivirine
     US9 12 (27.1)(27.1)— 
     Intl237 247 (4.2)9.8(14.0)
     WW245 259 (5.2)8.2(13.4)
     PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
     US372380(2.2)(2.2)— 
     Intl112137(17.9)(6.3)(11.6)
     WW485517(6.4)(3.3)(3.1)
     OTHER INFECTIOUS DISEASES
     US1018(46.4)(46.4)— 
     Intl6882(17.1)(10.8)(6.3)
     WW7799(22.4)(17.2)(5.2)
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
THIRD QUARTER
% Change
20222021Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3) (Continued)
NEUROSCIENCE
US$91983510.0%10.0%—%
Intl763845(9.9)1.8(11.7)
WW1,6811,6800.05.9(5.9)
     CONCERTA / methylphenidate
     US413519.319.3—
     Intl117122(4.4)8.0(12.4)
     WW1581570.810.5(9.7)
     INVEGA SUSTENNA / XEPLION / INVEGA
     TRINZA / TREVICTA
     US6846485.35.3—
     Intl348355(2.3)12.2(14.5)
     WW1,0311,0042.67.8(5.2)
     RISPERDAL CONSTA
     US6771(6.1)(6.1)—
     Intl5269(24.2)(11.3)(12.9)
     WW119140(14.9)(8.6)(6.3)
     OTHER NEUROSCIENCE
     US1278157.257.2—
     Intl246298(17.9)(10.0)(7.9)
     WW374379(1.9)4.3(6.2)
ONCOLOGY
US1,8121,52518.818.8—
Intl2,2522,1405.220.9(15.7)
WW4,0643,66510.920.0(9.1)
     DARZALEX
     US1,097 841 30.330.3—
     Intl955 739 29.348.2(18.9)
     WW2,052 1,580 29.838.7(8.9)
     ERLEADA
     US254 214 19.119.1—
     Intl235 130  *  *    *
     WW490 344 42.251.2(9.0)
     IMBRUVICA
     US353 413 (14.6)(14.6)—
     Intl559 654 (14.6)(2.5)(12.1)
     WW911 1,066 (14.6)(7.2)(7.4)
     ZYTIGA / abiraterone acetate
     US1625 (33.1)(33.1)—
     Intl440523(15.9)(1.2)(14.7)
     WW456548(16.7)(2.6)(14.1)
     OTHER ONCOLOGY
     US92 32 **—
     Intl6494(32.1)(22.6)(9.5)
     WW15512623.130.2(7.1)
See footnotes at end of schedule


Johnson & Johnson
Segment Sales
(Dollars in Millions)
THIRD QUARTER
% Change
20222021Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3) (Continued)
PULMONARY HYPERTENSION
US$604 610 (1.1)%(1.1)%— %
Intl247 258 (3.8)12.5 (16.3)
WW852 868 (1.9)3.0 (4.9)
     OPSUMIT
     US289 299 (3.4)(3.4)— 
     Intl152 159 (4.7)11.6 (16.3)
     WW441 458 (3.9)1.8 (5.7)
     UPTRAVI
     US283 265 6.6 6.6 — 
     Intl50 44 14.2 29.5 (15.3)
     WW333 309 7.7 9.9 (2.2)
     OTHER PULMONARY HYPERTENSION
     US33 47 (29.5)(29.5)— 
     Intl46 54 (15.7)1.2 (16.9)
     WW78 101 (22.1)(12.9)(9.2)
CARDIOVASCULAR / METABOLISM / OTHER
US8378004.5 4.5 — 
Intl198241(17.5)(8.8)(8.7)
WW1,0341,041(0.6)1.4 (2.0)
     XARELTO
     US689 636 8.4 8.4 — 
     Intl— — — — — 
     WW689 636 8.4 8.4 — 
     INVOKANA / INVOKAMET
     US49 66 (25.8)(25.8)— 
     Intl60 67 (11.0)(2.5)(8.5)
     WW109 133 (18.4)(14.1)(4.3)
     OTHER
     US98 98 (0.1)(0.1)— 
     Intl138 173 (20.0)(11.3)(8.7)
     WW236 271 (12.8)(7.3)(5.5)
TOTAL PHARMACEUTICAL
US7,4387,2213.0 3.0 — 
Intl5,7765,6612.0 16.7 (14.7)
WW$13,21412,8822.6 %9.0 %(6.4)%
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
THIRD QUARTER
% Change
20222021Reported
Operational (1)
Currency
MEDTECH SEGMENT (2) (3) (5)
INTERVENTIONAL SOLUTIONS
US$547 444 23.2 %23.2 %— %
Intl513 5130.0 13.0 (13.0)
WW1,060 95710.8 17.7 (6.9)
ORTHOPAEDICS
US1,309 1,249 4.8 4.8 — 
Intl785 843 (6.9)4.6 (11.5)
WW2,095 2,093 0.1 4.7 (4.6)
     HIPS
     US228 209 9.1 9.1 — 
     Intl124 146 (15.1)(4.5)(10.6)
     WW352 355 (0.9)3.5 (4.4)
     KNEES
     US203 184 9.8 9.8 — 
     Intl115 131 (12.8)(2.1)(10.7)
     WW317 316 0.4 4.9 (4.5)
     TRAUMA
     US473 455 3.8 3.8 — 
     Intl244 260 (6.0)6.5 (12.5)
     WW717 715 0.2 4.8 (4.6)
     SPINE, SPORTS & OTHER
     US406 401 1.3 1.3 — 
     Intl303 306 (1.1)10.2 (11.3)
     WW708 706 0.3 5.2 (4.9)
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
THIRD QUARTER
% Change
20222021Reported
Operational (1)
Currency
MEDTECH SEGMENT (2) (3) (5) (Continued)
SURGERY
US$984 948 3.7 3.7 — %
Intl1,439 1,457 (1.2)9.3 (10.5)
WW2,422 2,405 0.7 7.1 (6.4)
     ADVANCED
US457 440 3.8 3.8 — 
Intl701 705 (0.4)9.8 (10.2)
WW1,158 1,144 1.2 7.5 (6.3)
     GENERAL
US527 508 3.6 3.6 — 
Intl737 752 (2.0)8.8 (10.8)
WW1,264 1,261 0.3 6.7 (6.4)
VISION
US517 475 8.8 8.8 — 
Intl689 714 (3.5)8.4 (11.9)
WW1,206 1,189 1.4 8.6 (7.2)
     CONTACT LENSES / OTHER
US405 359 12.6 12.6 — 
Intl503 522 (3.6)9.5 (13.1)
WW908 882 3.0 10.8 (7.8)
     SURGICAL
US112 117 (3.2)(3.2)— 
Intl186 191 (3.3)5.6 (8.9)
WW298 308 (3.2)2.3(5.5)
TOTAL MEDTECH
US3,356 3,117 7.7 7.7 — 
Intl3,426 3,527 (2.9)8.5 (11.4)
WW$6,782 6,644 2.1 %8.1 %(6.0)%
See footnotes at end of schedule








Johnson & Johnson
Segment Sales
(Dollars in Millions)
NINE MONTHS
% Change
20222021Reported
Operational (1)
Currency
CONSUMER HEALTH SEGMENT (2) (3)
OTC
US$2,0281,9603.5 %3.5 %— %
Intl2,4342,2239.5 16.3 (6.8)
WW4,4624,1836.7 10.3 (3.6)
SKIN HEALTH / BEAUTY
US1,7641,862(5.3)(5.3)— 
Intl1,5001,595(6.0)1.5 (7.5)
WW3,264 3,457(5.6)(2.2)(3.4)
ORAL CARE
US471478(1.5)(1.5)— 
Intl664762(12.8)(7.2)(5.6)
WW1,135 1,240 (8.5)(5.0)(3.5)
BABY CARE
US264288(8.2)(8.2)— 
Intl840879(4.4)0.8 (5.2)
WW1,105 1,167 (5.4)(1.5)(3.9)
WOMEN'S HEALTH
US99(2.8)(2.8)— 
Intl674675(0.1)8.0 (8.1)
WW684684(0.1)7.8 (7.9)
WOUND CARE / OTHER
US366390(6.0)(6.0)— 
Intl170186(8.2)(5.4)(2.8)
WW537575(6.7)(5.8)(0.9)
TOTAL CONSUMER HEALTH
US4,903 4,987 (1.7)(1.7)— 
Intl6,283 6,320 (0.6)6.0 (6.6)
WW$11,186 11,307 (1.1)%2.6 %(3.7)%
See footnotes at end of schedule


Johnson & Johnson
Segment Sales
(Dollars in Millions)
NINE MONTHS
% Change
20222021Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3)
IMMUNOLOGY
US$8,2307,9323.8 %3.8 %— %
Intl4,5874,4642.8 12.9 (10.1)
WW12,81712,3953.4 7.1 (3.7)
     REMICADE
     US1,0991,508(27.1)(27.1)— 
     US Exports (4)
163197(17.2)(17.2)— 
     Intl606721(16.0)(11.9)(4.1)
     WW1,8682,426(23.0)(21.8)(1.2)
     SIMPONI / SIMPONI ARIA
     US8868405.4 5.4 — 
     Intl797877(9.2)0.4 (9.6)
     WW1,6821,717(2.0)2.9 (4.9)
     STELARA
     US4,7664,3968.4 8.4 — 
     Intl2,5712,4046.9 18.2 (11.3)
     WW7,3366,8007.9 11.9 (4.0)
     TREMFYA
     US1,303 975 33.6 33.6 — 
     Intl613 459 33.7 49.0 (15.3)
     WW1,916 1,434 33.6 38.5 (4.9)
     OTHER IMMUNOLOGY
     US14 15 (3.5)(3.5)— 
     Intl03 **  *
     WW14 18 (19.3)(19.3)0.0
INFECTIOUS DISEASES
US1,2661,635(22.6)(22.6)— 
Intl2,6421,75850.3 67.1 (16.8)
WW3,9083,39415.2 23.9 (8.7)
     COVID-19 VACCINE
     US120421(71.5)(71.5)— 
     Intl1,370346**  *
     WW1,490766**  *
     EDURANT / rilpivirine
     US27 31 (14.5)(14.5)— 
     Intl691 733 (5.7)4.8 (10.5)
     WW718 764 (6.1)4.0 (10.1)
     PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
     US1,0961,128(2.9)(2.9)— 
     Intl354440(19.5)(11.2)(8.3)
     WW1,4501,568(7.5)(5.2)(2.3)
     OTHER INFECTIOUS DISEASES
     US2455(57.2)(57.2)— 
     Intl228240(5.0)0.2 (5.2)
     WW251295(14.8)(10.6)(4.2)
See footnotes at end of schedule


Johnson & Johnson
Segment Sales
(Dollars in Millions)
NINE MONTHS
% Change
20222021Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3) (Continued)
NEUROSCIENCE
US$2,6582,4488.6 %8.6 %— %
Intl2,4982,751(9.2)(0.6)(8.6)
WW5,1565,199(0.8)3.7 (4.5)
     CONCERTA / methylphenidate
     US114117(2.2)(2.2)—
     Intl362372(2.6)6.5(9.1)
     WW476489(2.5)4.4(6.9)
     INVEGA SUSTENNA / XEPLION / INVEGA
     TRINZA / TREVICTA
     US2,0361,8828.1 8.1 —
     Intl1,0971,111 (1.3)9.4 (10.7)
     WW3,1322,9944.6 8.6 (4.0)
     RISPERDAL CONSTA
     US195210(7.1)(7.1)—
     Intl178242(26.3)(17.0)(9.3)
     WW373452(17.4)(12.4)(5.0)
     OTHER NEUROSCIENCE
     US31323931.131.1—
     Intl8611,026(16.2)(10.2)(6.0)
     WW1,1741,265(7.3)(2.4)(4.9)
ONCOLOGY
US5,0734,36416.216.2—
Intl6,983 6,406 9.020.8(11.8)
WW12,05610,77011.919.0(7.1)
     DARZALEX
     US3,071 2,302 33.433.4—
     Intl2,823 2,076 36.050.8(14.8)
     WW5,894 4,378 34.641.6(7.0)
     ERLEADA
     US693 578 20.020.0—
     Intl647 329  *  *  *
     WW1,340 907 47.754.9(7.2)
     IMBRUVICA
     US1,072 1,311 (18.3)(18.3)—
     Intl1,847 1,996 (7.5)1.9(9.4)
     WW2,918 3,307 (11.8)(6.1)(5.7)
     ZYTIGA / abiraterone acetate
     US54 96 (43.4)(43.4)—
     Intl1,4461,653(12.5)(1.9)(10.6)
     WW1,5001,749(14.2)(4.2)(10.0)
     OTHER ONCOLOGY
     US183 76 **—
     Intl220352(37.5)(31.2)(6.3)
     WW403428(5.9)(0.8)(5.1)
See footnotes at end of schedule






Johnson & Johnson
Segment Sales
(Dollars in Millions)
NINE MONTHS
% Change
20222021Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3) (Continued)
PULMONARY HYPERTENSION
US$1,736 1,778 (2.4)%(2.4)%— %
Intl810 821 (1.3)10.5 (11.8)
WW2,547 2,599 (2.0)1.7 (3.7)
     OPSUMIT
     US827 861 (4.0)(4.0)— 
     Intl495 510 (3.0)8.7 (11.7)
     WW1,322 1,371 (3.6)0.7 (4.3)
     UPTRAVI
     US824 792 3.9 3.9 — 
     Intl162 135 20.4 32.1 (11.7)
     WW986 927 6.3 8.0 (1.7)
     OTHER PULMONARY HYPERTENSION
     US86 125 (31.3)(31.3)— 
     Intl154 176 (13.0)(1.0)(12.0)
     WW239 301 (20.5)(13.5)(7.0)
CARDIOVASCULAR / METABOLISM / OTHER
US2,2662,379(4.8)(4.8)— 
Intl651727(10.4)(3.8)(6.6)
WW2,9163,106(6.1)(4.5)(1.6)
     XARELTO
US1,806 1,794 0.7 0.7 — 
Intl— — — — — 
WW1,806 1,794 0.7 0.7 — 
     INVOKANA / INVOKAMET
US164 249 (34.1)(34.1)— 
Intl193 194 (0.6)6.1 (6.7)
WW357 443 (19.5)(16.6)(2.9)
     OTHER
US295 336 (12.2)(12.2)— 
Intl458 533 (14.0)(7.3)(6.7)
WW753 869 (13.3)(9.2)(4.1)
TOTAL PHARMACEUTICAL
US21,22920,5363.4 3.4 — 
Intl18,17116,9277.3 18.5 (11.2)
WW$39,40037,4635.2 %10.2 %(5.0)%
See footnotes at end of schedule


Johnson & Johnson
Segment Sales
(Dollars in Millions)
NINE MONTHS
% Change
20222021Reported
Operational (1)
Currency
MEDTECH SEGMENT (2) (3) (5)
INTERVENTIONAL SOLUTIONS
US$1,566 1,353 15.7 %15.7 %— %
Intl1,6361,5992.3 11.1 (8.8)
WW3,2022,9528.5 13.2 (4.7)
ORTHOPAEDICS
US3,936 3,821 3.0 3.0 — 
Intl2,504 2,611 (4.1)4.3 (8.4)
WW6,440 6,433 0.1 3.5 (3.4)
     HIPS
     US693 651 6.5 6.5 — 
     Intl437 451 (3.3)4.6 (7.9)
     WW1,129 1,102 2.5 5.7 (3.2)
     KNEES
     US620 579 6.9 6.9 — 
     Intl386 403 (4.4)3.7 (8.1)
     WW1,005 983 2.3 5.6 (3.3)
     TRAUMA
     US1,412 1,352 4.4 4.4 — 
     Intl749 805 (7.0)2.3 (9.3)
     WW2,161 2,157 0.2 3.6 (3.4)
     SPINE, SPORTS & OTHER
     US1,211 1,239 (2.2)(2.2)— 
     Intl933 952 (2.0)6.1 (8.1)
     WW2,144 2,190 (2.1)1.4 (3.5)
See footnotes at end of schedule


Johnson & Johnson
Segment Sales
(Dollars in Millions)
NINE MONTHS
% Change
20222021Reported
Operational (1)
Currency
MEDTECH SEGMENT (2)(3)(5) (Continued)
SURGERY
US$2,897 2,881 0.5 %0.5 %— %
Intl4,410 4,418 (0.2)7.3 (7.5)
WW7,306 7,299 0.1 4.6 (4.5)
     ADVANCED
US1,328 1,304 1.8 1.8 — 
Intl2,132 2,126 0.3 7.2 (6.9)
WW3,460 3,430 0.9 5.2 (4.3)
     GENERAL
US1,569 1,577 (0.5)(0.5)— 
Intl2,277 2,292 (0.6)7.3 (7.9)
WW3,846 3,869 (0.6)4.1 (4.7)
VISION
US1,534 1,414 8.5 8.5 — 
Intl2,170 2,103 3.2 12.9 (9.7)
WW3,704 3,517 5.3 11.1 (5.8)
     CONTACT LENSES / OTHER
US1,179 1,082 9.0 9.0 — 
Intl1,533 1,525 0.5 11.1 (10.6)
WW2,712 2,607 4.0 10.2 (6.2)
     SURGICAL
US355 333 6.8 6.8 — 
Intl637 577 10.3 17.6 (7.3)
WW992 910 9.0 13.6 (4.6)
TOTAL MEDTECH
US9,932 9,470 4.9 4.9 — 
Intl10,719 10,731 (0.1)8.2 (8.3)
WW$20,651 20,201 2.2 %6.6 %(4.4)%
Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-
rounded figures and, therefore, may not recalculate precisely.
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Certain prior year amounts have been reclassified to conform to current year product disclosures
(4) Reported as U.S. sales
(5) Previously referred to as Medical Devices









Supplemental Sales Reconciliation (Unaudited)
(Dollars in Millions)
THIRD QUARTER
Percent Change
20222021TotalOperationsCurrency
Pharmaceutical
U.S.$7,438  7,221  3.0 % 3.0  -
International 5,776  5,661  2.0  16.7  (14.7)
Worldwide 13,214  12,882  2.6  9.0  (6.4)
COVID-19 Vaccine
U.S. 0  270  *  *  -
International 489  233  *  *    *
Worldwide 489  502  (2.7) 13.1  (15.8)
Pharmaceutical excluding COVID-19 Vaccine
U.S. 7,438  6,951  7.0  7.0  -
International 5,287  5,429  (2.6) 11.3  (13.9)
Worldwide 12,725  12,380  2.8  8.9  (6.1)
Worldwide
U.S. 12,453  11,963  4.1  4.1  -
International 11,338  11,375  (0.3) 12.3  (12.6)
Worldwide 23,791  23,338  1.9  8.1  (6.2)
COVID-19 Vaccine
U.S. 0  270  *  *  -
International 489  233  *  *    *
Worldwide 489  502  (2.7) 13.1  (15.8)
Worldwide
U.S. 12,453  11,693  6.5  6.5  -
International 10,849  11,143  (2.6) 9.5  (12.1)
Worldwide excluding COVID-19 Vaccine$23,302  22,836  2.0 % 8.0  (6.0)
Note: Columns and rows within tables may not add due to rounding
* Percentage greater than 100% or not meaningful












Supplemental Sales Reconciliation (Unaudited)
(Dollars in Millions)
NINE MONTHS
Percent Change
20222021TotalOperationsCurrency
Pharmaceutical
U.S.$21,229  20,536  3.4 % 3.4  -
International 18,171  16,927  7.3  18.5  (11.2)
Worldwide 39,400  37,463  5.2  10.2  (5.0)
COVID-19 Vaccine
U.S. 120  421  (71.5) (71.5) -
International 1,370  346  *  *    *
Worldwide 1,490  766  *  *    *
Pharmaceutical excluding COVID-19 Vaccine
U.S. 21,109  20,115  4.9  4.9  -
International 16,801  16,582  1.3  11.7  (10.4)
Worldwide 37,910  36,697  3.3  8.0  (4.7)
Worldwide
U.S. 36,064  34,993  3.1  3.1  -
International 35,173  33,978  3.5  12.9  (9.4)
Worldwide 71,237  68,971  3.3  7.9  (4.6)
COVID-19 Vaccine
U.S. 120  421  (71.5) (71.5) -
International 1,370  346  *  *    *
Worldwide 1,490  766  *  *    *
Worldwide
U.S. 35,944  34,572  4.0  4.0  -
International 33,803  33,633  0.5  9.5  (9.0)
Worldwide excluding COVID-19 Vaccine$69,747  68,205  2.3 % 6.7  (4.4)
Note: Columns and rows within tables may not add due to rounding
* Percentage greater than 100% or not meaningful